JW Therapeutics Announces NMPA Acceptance of the Supplemental Biological License Application for Carteyva(R) in Patients with Relapsed or Refractory Mantle Cell Lymphoma

JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that the National Medical Products Administration (NMPA) of China

Related Keywords

China ,Markj Gilbert ,Chinj Hematol ,China National Medical Products Administration ,Bristol Myers Squibb ,National Medical Products Administration ,National Significant New Drug Development Program ,Biological License Application ,Mantle Cell Lymphoma ,Breakthrough Therapy Designation ,Priority Review ,Chief Medical Officer ,Overall Survival ,Advanced Stage Mantle Cell ,Clinical Oncology ,Refractory Mantle Cell Lymphoma ,Relmacabtagene Autoleucel Injection ,Juno Therapeutics ,